Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer

Raffaella Santoro1, Marco Zanotto1, Francesca Simionato2, Camilla Zecchetto2, Valeria Merz2, Chiara Cavallini2, Geny Piro1, Fabio Sabbadini1, Federico Boschi4, Aldo Scarpa5, and Davide Melisi1,2

Abstract

YAP and TAZ are central determinants of malignancy; however, their functions remain still undruggable. We identified TGFβ-activated kinase 1 (TAK1) as a central hub integrating the most relevant signals sustaining pancreatic cancer aggressiveness and chemoresistance. Glycogen synthase kinase (GSK)3 is known to stabilize TAK1, and its inhibition causes a reduction in TAK1 levels. Here, we hypothesized that TAK1 could sustain YAP/TAZ program, and thus, modulation of TAK1 expression through the inhibition of GSK3 could impair YAP/TAZ functions in pancreatic cancer.

Differentially expressed transcripts between pancreatic cancer cells expressing scramble or TAK1-specific shRNA were annotated for functional interrelatedness by ingenuity pathway analysis. TAK1 expression was modulated by using different GSK3 inhibitors, including LY2090314. In vivo activity of LY2090314 alone or in combination with nab-paclitaxel was evaluated in an orthotopic nude mouse model.

Introduction

Pancreatic cancer is among the most lethal and inadequately understood human malignancies (1, 2), and will seemingly become the second leading cause of cancer-related death by 2030 in Western countries. Pancreatic cancer patients’ prognosis is a dismal, mainly because of the early metastatic behavior of the disease, its aggressiveness, and it is the unique resistance to standard of care chemotherapeutic agents (3).

The transcriptional regulators Yes Associated Protein (YAP) and transcriptional coactivator with a PDZ-binding domain (TAZ) are emerging as central determinants of malignancy, due to their major role in sustaining initiation, progression, metastasis, and chemoresistance of tumors, and inducing cancer stem cells phenotype. In pancreatic cancer, YAP represents a critical oncogenic effector of KRAS-initiated tumor progression (4). The survival of KRAS addicted tumor cells was recently associated to YAP1 activation (5). Moreover, YAP activation was necessary to sustain KRAS-independent spontaneous recurrence of pancreatic cancer developed in KRASG12D-inactivated mice (6). However, the activity of these transcriptional regulators remains still undruggable to date, and just the dissection of the different signaling pathways that sustain their activation could facilitate the development of new therapeutic approaches (7). Although the Hippo pathway is acknowledged as the main regulator of YAP/TAZ, recent studies have identified novel upstream signaling pathways widening the complexity of their regulation (8).

TAK1 is a serine/threonine kinase constituting the cellular hub for several cytokine-mediated signaling, which critically regulates inflammatory responses and cell survival (9, 10) by controlling the activation of transcription factors such as AP-1 and NF-κB (11, 12). We demonstrated that targeting the kinase activity of TAK1 dramatically led to a proapoptotic phenotype and, in turn, to a significantly higher sensitivity to chemotherapy and radiotherapy in pancreatic (13) and esophageal carcinoma (14). Despite the variety of compounds targeting TAK1 kinase activity, none of them has progressed into clinical development to date.

Glycogen synthase kinase (GSK)3 is a multifunctional serine/threonine kinase that is encoded by 2 closely related genes, GSK-3α and GSK-3β. GSK3 has been implicated in a number of human malignancies, including pancreatic cancer. In particular, a recent study demonstrated that GSK-3α interacts with TAK1 thus stabilizing the TAK1–TAB complex. This promotes noncanonical NF-κB signaling in pancreatic cancer cells. Pharmacologic inhibition of GSK-3 caused a significant reduction of TAK1 levels (15).

In this study, we explored novel downstream signaling of TAK1, and hypothesized that this kinase could sustain the essential role of YAP/TAZ program in pancreatic cancer. Thus, targeting TAK1...
expression by inhibiting GSK3 could suppress YAP/TAZ expression and modulate, in turn, their contribution to the malignancy and treatment resistance of this disease.

Materials and Methods

Cell cultures and reagents

Human pancreatic cancer cell lines AsPC1, Panc1, were purchased from the ATCC. MDA-Panc28 cell line was a kind gift by Dr. Paul J. Chiao. Panc1, AsPC1, and MDA-Panc28 pancreatic cancer cell lines silenced for the expression of TAK1 were established as described by Melisi and colleagues (13). All cell lines used in this study were cultured as monolayers at 37°C, 5% CO2 in high glucose DMEM (Catalog No. 41966-029; Life Technologies), supplemented with 10% heat-inactivated FBS (Catalog No. 10270-106; Life Technologies), 2 mmol/L l-glutamine (Catalog No. BE17-605E; Lonza), 100 IU/mL penicillin and 100 μg/mL streptomycin (Catalog No. 15140-122; Life Technologies), and kept in culture for maximum 1 month. All cell lines used in this study were authenticated using DNA fingerprinting at the genomics core facility at Wayne State University (2009) and routinely tested for mycoplasma presence using the MycoAlert Mycoplasma Detection Kit (Catalog No. LT07-118; Lonza).

((Z)-7-oxozeaenol TAK1 kinase selective inhibitor (TOCRIS Bioscience) was dissolved in 100% DMSO at a stock concentration of 10 mmol/L (16). Lithium chloride (Catalog No. L4408), a nonspecific oral GSK3 inhibitor (IC50 = 10 mmol/L) was purchased by AppliChem and was dissolved in sterile water at a stock concentration of 5 mmol/L. A working concentration of 20 mmol/L has been used in all the in vitro assays. LY2090314 (Catalog No. S7063) and CHIR-99021 (Catalog No. S1263) were purchased from Selleckchem and dissolved in DMSO. Gemicitabine (Accord), oxaliplatin (Accord), SN38 (Campto, ref. 17), and nab-paclitaxel (Celgene) were used at the indicated concentrations for the indicated time. The proteasome inhibitor MG132 (Z-Leu-Leu-Leu-al, C2211; Sigma-Aldrich) was dissolved in 100% DMSO and used at 5 μmol/L concentration for 24 hours. For in vivo experiments, LY2090414 was dissolved in 5% Tween-80 (A4743; AppliChem) in saline. Drug interactions were studied for synergistic effect according to Chou and Talalay method (24) and equal amounts (20–50 μg of protein extract) were loaded onto SDS-PAGE (4%–20%) and transferred to polyvinylidene fluoride membranes (Immobilon-P, Catalog No. IPVH00010; Millipore). Immunoblots were performed using the indicated antibodies. Antibodies to TAK1 (ab109526, 1:1,000), ITCH (ab100918, 1:1,000), TRAF6 (ab94720, 1:1,000), Ub-K63 (ab179434, 1:1,000) were all purchased from Abcam. YAP/TAZ (sc-101199, 1:1,000), CTGF (sc-14939, 1:1,000), GAPDH (sc-166545, 1:1,000), and CHIR-99021 were shown in Supplementary Fig. S1A.

Gene expression microarrays and pathway analysis

Total RNA was extracted using TRIzol reagent (Catalog No. 15596-018; Life Technologies) following manufacturer’s instruction. RNA quality was assessed by agarose gel electrophoresis. Total RNA was quantified by reading the absorbance at 260 nm using a Nanodrop (Thermo Fisher Scientific). Differences in gene expression between control and silenced TAK1 cells were examined using Illumina Human 48K gene chips (D-103-0204; Illumina) as previously described in ref. 19. Briefly, 300 ng total RNA were reverse-transcribed and cRNA was synthesized and biotinylated using the IlluminaTotalPrep RNA Amplification Kit (AM11791; Ambion). cRNAs (750 ng) were hybridized using Illumina Human 48K gene chips (Human HT-12 V4 BeadChip). Array were washed with Illumina High Temp Wash Buffer for 10 minutes at 55°C, and stained with streptavidin-Cy3 dyes (Amersham Biosciences). The Illumina Genome Studio software (Genome Studio V2011.1) was used to obtain probe intensity. Raw data were Loess normalized with the Lumi R package and further processed with Excel software. Each microarray experiment was repeated twice. Network and functional interrelatedness were studied for the differentially expressed genes using the Ingenuity Pathway Analyses (IPA) software program (Ingenuity Systems).

Cell transduction

The expression vector for either murine wild-type TAK1 or murine kinase-dead K63W TAK1 (20) and packaging vectors were cotransfected into 293T cells. Seventy-two hours posttransfection, supernatants containing virus were filtered through a 0.45 μm filter (Corning, Inc.). AsPC-1, PANc-1, and MDA-Panc-28 cells were transduced by the lentivirus in the presence of the polycation polybrene and lysed 72 hours post infection to obtain cellular extracts.

Reverse transcription and qRT-PCR

Differences in gene expression were measured as described previously (21). Total RNA was extracted using TRIzol reagent and quantified by Nanodrop. One microgram of RNA was reverse-transcribed with High Capacity cDNA Reverse Transcription Kit (Catalog No. 4368814; Applied Biosystems) following manufacturer’s instruction. cDNA was diluted 1:10 and subjected to RT-PCR using FAST PowerUp SYBR green mastermix (Catalog No. A25742; Applied Biosystems). Primers were purchased by Life Technologies and used at 0.2 μmol/L final concentration. Changes in gene expression were normalized to β-actin and quantified using the 2−ΔΔCt method.

Protein extraction and Western blotting

Western blot analyses were performed as described in ref. 22. Total protein extracts were prepared by lysing cells in radioimmunoprecipitation assay buffer (50 mmol/L Tris HCl (pH 8), 150 mmol/L NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate). All protein extracts were quantified by BCA Protein Assay Kit (23225; Thermo Fisher Scientific) and equal amounts (20–50 μg of protein extract) were loaded onto SDS-PAGE (4%–20%) and transferred to polyvinylidene fluoride membranes (Immobilon-P, Catalog No. IPVH00010; Millipore). Immunoblots were performed using the indicated antibodies. Antibodies to TAK1 (ab109526, 1:1,000), ITCH (ab100918, 1:1,000), TRAF6 (ab94720, 1:1,000), Ub-K63 (ab179434, 1:1,000) were all purchased from Abcam. YAP/TAZ (sc-101199, 1:1,000), CTGF (sc-14939, 1:1,000), GAPDH (sc-166545, 1:1,000), and CHIR-99021 were shown in Supplementary Fig. S1A.

Transwell migration assays

Differences in cancer cells migration were measured as described previously (23). Briefly, 5 × 105 cells were allowed to migrate for 20 hours. Following removal of nonmigrating cells, cells migrated to the bottom layer of the transwell insert were stained with DAPI. Each membrane was scanned by fluorescence microscopy (EVOS FL Auto; Thermo Fisher Scientific) and all the cells were automatically counted using ImageJ software. Samples were analyzed in triplicate and percentage of cells relative to control is shown in the graphs. P values were calculated by Student t test.

Cancer stem cells and colony-forming assays

A total of 5 × 102 cells were seeded in 6 wells plates and grown for 15 days. To maintain good growth conditions, the medium was...
changed every 48 hours. Cells were stained for 30 minutes with 0.1% crystal violet dissolved in 10% of formaldehyde. Cells were washed 3 times with water and colonies were counted by automatic microscopy (EVOS FL Auto; Thermo Fisher Scientific). Differences in cancer stem cells were measured as described previously (24).

**Nude mouse orthotopic xenograft models**

Five-weeks-old female athymic nude mice (Crl:CD1-Foxn1nu, CDNNSSE055) were purchased from Charles River. Guidelines of the University of Verona Animal Ethic Committee were followed to house animals in specific pathogen-free conditions and treat them. Subconfluent cultures of pancreatic cancer cells were collected using 0.05% trypsin-EDTA ( Gibco; ref. 25). To stimulate tumor growth, cells were resuspended in a solution of Matrigel: PBS at 1:0 × 10^7 cells/μL concentration (Matrigel Matrix Growth Factor; 356230; BD Biosciences). Orthotopic injection of pancreatic cancer cells was performed as previously described in ref. 25. We did not observe anesthesia-related deaths.

**Antitumor activity of LY2090314 plus nab-paclitaxel in vivo in AsPC1 pancreatic tumor orthotopic xenografts**

AsPC1 orthotopic tumor-bearing mice were randomly assigned (n = 11 per group) to receive the following on a weekly schedule: (i) vehicle (5% Tween-80 in saline) intraperitoneally (days 1–3–5); (ii) LY2090314 (2.5 mg/kg i.p., days 1–3); (iii) nab-paclitaxel (3 mg/kg i.p., day 5); and their combinations: (iv) nab-paclitaxel (3 mg/kg i.p., day 5) plus LY2090314 (2.5 mg/kg i.p., days 1–3). Treatments were continued until progression.

Weight and tumor growth were measured weekly. When a prominent mass was present in the mouse abdomen (tumor volume ≥2,000 mm^3), mice were euthanized by cervical dislocation, and that was considered the day of death for survival evaluation. The median survival duration was reached when at least half of the mice in each treatment group were sacrificed.

**Immunohistochemistry**

Formalin-fixed paraffin-embedded tissue sections were subjected to immunostaining using the streptavidin–peroxidase technique, with diaminobenzidine (Imprint DAB, SK-4105; Vector Lab) as a chromogen, as previously described in ref. 26. Either citrate pH 6.0 (ab110239, 1:1,000), CTGF (ab6992, 1:600), AXL (ab72069, 1:100), and BACE1 (ab100193, 1:300) or combinations of (i) human AXL (3 mg/kg i.p., day 5) and human BACE1 (3 mg/kg i.p., day 3); (ii) human AXL (3 mg/kg i.p., day 5) plus human BACE1 (3 mg/kg i.p., days 1–3); or (iii) BACE1 and CTGF used as antigen retrieval buffers. Abcam primary rabbit monoclonal antibody, as previously described in ref. 26. Either citrate pH 6.0 (ab110239, 1:1,000), CTGF (ab6992, 1:600), AXL (ab72069, 1:100), and BACE1 (ab100193, 1:300) or combinations of (i) human AXL (3 mg/kg i.p., day 5) and human BACE1 (3 mg/kg i.p., day 3); (ii) human AXL (3 mg/kg i.p., day 5) plus human BACE1 (3 mg/kg i.p., days 1–3); or (iii) BACE1 and CTGF used as antigen retrieval buffers. Abcam primary rabbit monoclonal antibody, as previously described in ref. 26. Either citrate pH 6.0 (ab110239, 1:1,000), CTGF (ab6992, 1:600), AXL (ab72069, 1:100), and BACE1 (ab100193, 1:300) or combinations of (i) human AXL (3 mg/kg i.p., day 5) and human BACE1 (3 mg/kg i.p., day 3); (ii) human AXL (3 mg/kg i.p., day 5) plus human BACE1 (3 mg/kg i.p., days 1–3); or (iii) BACE1 and CTGF used as antigen retrieval buffers. Abcam primary rabbit monoclonal antibody, as previously described in ref. 26. Either citrate pH 6.0 (ab110239, 1:1,000), CTGF (ab6992, 1:600), AXL (ab72069, 1:100), and BACE1 (ab100193, 1:300) or combinations of (i) human AXL (3 mg/kg i.p., day 5) and human BACE1 (3 mg/kg i.p., day 3); (ii) human AXL (3 mg/kg i.p., day 5) plus human BACE1 (3 mg/kg i.p., days 1–3); or (iii) BACE1 and CTGF used as antigen retrieval buffers. Abcam primary rabbit monoclonal antibody, as previously described in ref. 26.

**Results**

**TAK1 prevents YAP/TAZ prostate degradation**

To identify novel downstream signaling of TAK1 that could drive the aggressiveness of pancreatic cancer, we analyzed differential gene expression (GEO accession number GSE137265, https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE137265) in AsPC1, Panc1, and MDA-Panc28 pancreatic cancer cell lines transduced with lentivirus expressing TAK1-specific shRNA (shTAK1) or scramble sequence as control (Fig. 1A) by using the IPA software. We found a significant and consistent association of the genes modulated by TAK1 silencing with the HIPPO, Wnt/β-catenin, and protein ubiquitination pathways (Fig. 1B). To deepen our insight into the regulation of the HIPPO pathway, we investigated whether YAP/TAZ expression was affected by TAK1 silencing. We measured a downregulation of YAP/TAZ proteins in stable shTAK1 cells as compared with their respective controls, as well as an upregulation of β-catenin (Fig. 1C), which was sustained by increased GSK3β and GSK3β phosphorylation in shTAK1 cell lines as compared with their controls (Supplementary Fig. S1B). Consistently, we measured a significant (∞ < 0.01) downregulation of the YAP/TAZ regulated genes DKK1, CTGF, and AXL in shTAK1 cells as compared with their respective controls (Fig. 1D). The same downregulation of YAP/TAZ was demonstrated in cells transiently transfected with siRNA sequences targeting TAK1 (Supplementary Fig. S1C), which corroborated our findings and ruled out the possibility that this could be due to shTAK1 off-target and/or long-term adaptive effects. However, when we measured YAP/TAZ mRNA levels, we did not observe a consistent significant downregulation of these genes in stable shTAK1 cells. A significant upregulation of YAP/TAZ mRNA levels was measured in MDA-Panc28 cells silenced for TAK1 expression as compared to their respective controls, which we interpreted as a compensatory effect (Fig. 1E).

To test whether the modulation of YAP/TAZ by silencing of TAK1 could be related to TAK1 kinase activity, we treated AsPC1, Panc1, and MDA-Panc28 pancreatic cancer cell lines with the TAK1 kinase inhibitors (S)-7-oxozeanol. Effective inhibition of TAK1 kinase activity was confirmed by suppression of IKK phosphorylation and decrease in BIRC3 levels (Supplementary Fig. S2A). However, the inhibition of TAK1 kinase activity did not decrease YAP/TAZ protein levels in the 3 pancreatic cancer cell lines under investigation (Fig. 2A).

Conversely, when we transduced stable shTAK1 cells with a murine K63W TAK1 kinase dead expressing vector, which could not be targeted by human-specific shRNA sequences, we measured a significant rescue of the downregulation of YAP/TAZ proteins at levels similar to those obtained by transducing them with a wild-type murine TAK1 sequence. Moreover, this rescue contributed to rule out potential shTAK1 off-target effects (Fig. 2B). Altogether, these results demonstrate that the expression of TAK1, rather than its kinase activity, could affect YAP/TAZ stability.

In this regard, we investigated whether proteasomal degradation could be involved in TAK1-mediated modulation of YAP/TAZ protein stability. Treatment with proteasome inhibitor bortezomib increased YAP/TAZ protein levels in all these cell lines. Interestingly, although we observed only a modest increase in YAP/TAZ protein levels in control cell lines, YAP/TAZ were strongly upregulated in shTAK1 cells upon proteasomal inhibition with both bortezomib (Fig. 2C) and MG-132 (Supplementary Fig. S2B). We investigated, thus, whether silencing of TAK1 could modulate the expression of either K48 or K63 ubiquitin ligases. We measured lower protein levels of TRAF6 and higher protein levels of ITCH in shTAK1 cells than in their respective controls (Fig. 2D), as well as a decrease in total K63 ubiquitinated proteins in shTAK1 cells than in their respective controls (Supplementary Fig. S3A). Hence, we performed specific K63-linked and K48-linked precipitations and we observed a decrease of K63-linked and an increase in K48-linked ubiquitinated YAP/TAZ in shTAK1 cells as compared with their respective control (Fig. 2E). Accordingly, YAP/TAZ immunoprecipitation followed by specific anti-K48 and anti-K63 ubiquitin immunoblot showed an increase in K48-ubiquitinated and a decrease in K63-ubiquitinated YAP/TAZ in cells silenced for TAK1 (Fig. 2F). To corroborate our data, we performed
co-immunoprecipitations in AsPC1, Panc1, and MDA-Panc28 cells and we demonstrated the existence of a protein complex between YAP/TAZ and TRAF6 (Supplementary Fig. S3B). Notably, we demonstrated that the presence of TAK1 was necessary for the formation of the YAP/TAZ–TRAF6 complex (Fig. 2G).

Altogether, these data demonstrate that, independently by its kinase activity, TAK1 protein levels can regulate YAP/TAZ protein stability by fostering their K63-ubiquitination versus K48-ubiquitination through the binding with TRAF6, thus preventing their proteasomal degradation.

Modulating TAK1 levels through GSK3 inhibition reduces YAP/TAZ protein levels and activities

To translate our findings into a therapeutic approach relevant for patients presenting with pancreatic cancer, we took advantage of the observation by Bang and colleagues (15) that GSK3 inhibition could reduce TAK1 stability. Thus, we hypothesized that GSK3 inhibition could be used to achieve a TAK1-mediated downregulation of YAP/TAZ proteins.

To obtain a pharmacologic modulation of TAK1 expression, we used 2 potent and highly selective inhibitors of GSK3α/β, LY2090314 and CHIR-99021, and the unselective GSK3 inhibitor LiCl, which acts in an uncompetitive manner by displacing a divalent cation required for GSK3 catalytic activity (27). This resulted in a substantial decrease of YAP/TAZ and TAK1 protein levels in all the 3 pancreatic cancer cell lines (Fig. 3A; Supplementary Fig. S4A). Treatment with the proteasome inhibitor Bortezomib partially restored TAK1 and YAP/TAZ protein levels (Fig. 3A). Similar to the TAK1 silencing, modulation of TAK1 expression induced by GSK3 inhibition resulted in a significant downregulation of YAP/TAZ regulated genes CTGF, AXL, and CYR61 in all the 3 pancreatic cancer cell lines (P < 0.05; Fig. 3B; Supplementary Fig. S4B). As obtained by silencing TAK1 expression, treatment with LY2090314 increased levels of GSK3 target β-catenin (Supplementary Fig. S4C). Similar effects were confirmed in FLO-1 and KYAE-1 esophageal cancer cell lines (Supplementary Fig. S5A and S5B).

YAP/TAZ are known as important mediators of cell proliferation, migration, anchorage-independent growth, and stemness (8); thus, we evaluated whether modulation of TAK1 expression induced by GSK3 inhibition would impair these processes. Indeed, we demonstrated that the selective GSK3 inhibitor LY2090314 significantly reduced cell proliferation in control pancreatic cancer cell lines in the same extent than did TAK1 silencing, while it was ineffective on TAK1 silenced counterpart (Fig. 3C). Moreover, the inhibition of GSK3 significantly reduced clonogenic potential (AsPC1, P < 0.001; Panc1, P < 0.001; MDA-Panc28, P < 0.01; Fig. 3D), and consistently and significantly impaired the migration ability of AsPC1, Panc1, and MDA-Panc28 cells (P < 0.05; Fig. 3E). Conversely, LY2090314 was completely
Figure 2.

TAK1 modulates YAP and TAZ ubiquitination. A, Immunoblot analysis of cells treated for 48 hours with the TAK1 kinase inhibitor (5Z)-7-oxozeaenol. Numbers indicate the normalized ratio of YAP/TAZ over GAPDH signals obtained by densitometric analysis. B, Immunoblot analysis of cells transduced with either K63W kinase-dead or wild-type TAK1. Numbers indicate the normalized ratio of YAP/TAZ over H3 signals obtained by densitometric analysis. C, Immunoblot analysis of cells treated with the proteasome inhibitor bortezomib. Numbers indicate the normalized ratio of YAP/TAZ over GAPDH signals obtained by densitometric analysis. D, ITCH and TRAF6 protein levels in the indicated cellular extracts. Numbers indicate the normalized ratio of the indicated proteins over GAPDH signals obtained by densitometric analysis. E, Assessment of YAP/TAZ ubiquitination by K63 and K48 specific pull-down in the indicated cell lines. F, Immunoblot analysis of immunoprecipitated YAP/TAZ using anti-K48- and anti-K63-specific antibodies in the indicated cell lines. Numbers indicate densitometric analysis. G, Immunoblot analysis of YAP/TAZ immunoprecipitated complexes using the indicated antibodies. Asterisks indicate IgG heavy chains.
Figure 3.
Pharmacologic inhibition of TAK1 by targeting GSK3 impairs YAP and TAZ levels and oncogenic activities. A, Immunoblot analyses of AsPC1, Panc1, and MDA-Panc28 cell lines treated with the GSK3 inhibitors LY2090314 or CHIR-99021 for 72 hours. Cell extracts were subjected to immunoblot with the indicated antibodies. Numbers indicate the normalized ratio of the indicated proteins over GAPDH signals obtained by densitometric analysis. B, mRNA expression levels of the indicated YAP/TAZ target genes over -actin from cells treated as in A. Error bars indicate SD.
C, Growth curves of ctrl and shTAK1 AsPC1 and Panc1 cell lines treated with LY2090314 3 μmol/L. Means and SD of measurements performed in quadruplicate are shown.
D, Colony formation assays of AsPC1, Panc1, and MDA-Panc28 treated with LiCl 20 mmol/L, LY2090314 3 μmol/L, or CHIR-99021 3 μmol/L for 72 hours, and allowed to form colonies. A representative image of colonies is shown on the left. Histograms show colony number. Error bars indicate SD.
E, AsPC1, Panc1, and MDA-Panc28 cells were seeded and either treated or not with LiCl 20 mmol/L, LY2090314 3 μmol/L, or CHIR-99021 3 μmol/L for 72 hours. Cells were then counted and seeded into the upper chamber of a transwell. Sample images of migrated cells are shown. Histograms show the percentage of migrated cells. Error bars indicate SD.

Santoro et al.
MOLECULAR CANCER THERAPEUTICS

Published OnlineFirst September 27, 2019; DOI: 10.1158/1535-7163.MCT-19-0270
Figure 4.
Targeting GSK3 reduces cancer stem cells features and chemoresistance of pancreatic cancer cell lines. A, AsPC1 (left histogram), Panc1, and MDA-Panc28 (right histograms) cell lines were pulsed for 72 hours with the indicated GSK3 inhibitors. 5 × 10⁵ cells were then seeded into ultra-low attachment 6-well plates and cultured in spheroids-forming medium for 52 days. Histograms show the percentage of CD133⁺, CXCR4⁺, CD24⁺, and CD44⁺ CSCs for Panc1 and MDA-Panc28-derived spheroids and CD133⁺, CXCR4⁺, CD24⁺, CD44⁺, and EpCAM⁺ CSCs for AsPC1, as measured by flow cytometry. Error bars indicate SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001. B, AsPC1, Panc1, and MDA-Panc28 cells were either treated or not with LY2090314 3 μmol/L or CHIR-99021 3 μmol/L for 72 hours. 20 × 10⁵ cells were then seeded into ultra-low attachment 96 wells plates in triplicate for 15 days to allow for spheroid formation. Pictures show Z-stack microphotographs of representative wells. Histograms show the average area of spheroids formed in each well. Error bars indicate SD. *, P < 0.05; **, P < 0.01; ***, P < 0.001. C, AsPC1, Panc1, and MDA-Panc28 cells were pretreated with LY2090314 3 μmol/L or dimethyl sulfoxide (DMSO) as control for 72 hours, and subsequently treated with equitoxic increasing doses of nab-paclitaxel and washed-out after 24 hours. Sulforhodamine B (SRB) assay was used to obtain relative estimates of viable cell number. Means and 95% confidence intervals are shown. Curves were fitted by nonlinear regression analysis. Combination index (CI) plot representing a quantitative measure of the degree of drug interaction for a given end point of the effect measurement is shown. D, Data were analyzed for Bliss independence. Dose matrix and synergy score are shown for each cell line.
ineffective in shTAK1 pancreatic cancer cell lines (Supplementary Fig. S6A and S6B).

GSK3 inhibition impaired stemness as measured by a significant reduction in both the percentage of CD133+, CXCR4+, CD24+, and CD44+ cancer stem cells (P < 0.05; Fig. 4A), and a decrease in the area of spheroids growing in low-anchorage conditions (P < 0.05; Fig. 4B) in all 3 pancreatic cancer cell lines, with the exception of CHIR-99021-treated MDA-Panc28.

Altogether, these data demonstrate that GSK3 inhibition impairs in vitro the aggressiveness of pancreatic cancer cells by targeting the more relevant oncogenic functions sustained by YAP and TAZ.

**GSK3 inhibitor LY2090314 modulates pancreatic cancer chemoresistance by targeting the TAK1–YAP/TAZ axis**

To test our hypothesis that the pharmacologic inhibition of GSK3 could be used to modulate the chemoresistance of pancreatic cancer by impairing YAP/TAZ prosurvival activities, including suppression of apoptosis as previously published in ref. 28, we initially demonstrated that the addition of LY2090314 resulted in an increase of Annexin V+ cells (Supplementary Fig. S7A) and PARP-1 cleavage (Supplementary Fig. S7B). AsPC1, Panc1, and MDA-Panc28 pancreatic cancer cells were, then, treated with increasing doses of classic chemotherapeutic agents nab-paclitaxel, gemcitabine, oxaliplatin, or the active metabolite of irinotecan SN-38 in combination with LY2090314, or DMSO as control. We demonstrated a highly synergistic effect between LY2090314 and these chemotherapeutic agents against the 3 different pancreatic cancer cell lines (Fig. 4C and D; Table 1; Supplementary Fig. S8A–S8C). Combination treatment of LY2090314 plus nab-paclitaxel resulted in a significant increase in PARP-1 cleavage (Fig. S7C). Contrariwise to the effect observed in pancreatic cancer cells, we measured a significant protective effect of LY2090314 on the cytotoxic activity of nab-paclitaxel in HPDE normal human pancreatic duct epithelial cells (Supplementary Fig. S7D).

To demonstrate that LY2090314 could cooperate with clinically relevant doses of nab-paclitaxel into an effective therapeutic approach to inhibit the growth of pancreatic cancer in vivo, we used an orthotopic xenograft nude mouse model. Forty mice were orthotopically injected with AsPC1 human pancreatic cancer cells and randomly assigned to 4 treatment groups (n = 10 per group). At the median survival duration of mice in the control group (day 62), LY2090314 and nab-paclitaxel as single agents were completely inactive. However, a statistically significant reduction in tumor volume was measured in the mice treated with their combination if compared with untreated controls (P < 0.05; Fig. 5A). Accordingly, we measure a significantly prolonged median survival duration only in mice treated with the LY2090314 plus nab-paclitaxel combination [Fig. 5B, median survival (days): control = 62; nab-paclitaxel = 64; LY2090314 = 62; LY2090314 plus nab-paclitaxel = 105, P < 0.05]. All regimens were well tolerated. We did not observe weight loss or other signs of toxicity (Supplementary Fig. S5D).

To confirm that the effects of LY2090314 treatment in vivo could be related to the modulation of the TAK1–YAP/TAZ axis, we assessed the expression of YAP/TAZ target genes in tumor specimens excised from mice belonging to the control and LY2090314 groups. As expected, we measured a relevant increase of the inhibitory Ser-21 phosphorylation of GSK3β in mice treated with LY2090314 (Fig. 5C). Ser-9 phosphorylation of GSK3β was also induced, although to a lesser extent. Consistently with the results in vitro, GSK3 inhibition led to a measurable decrease in TAK1 and YAP/TAZ protein expression and, in turn, to a reduction of the number of Ki67+ cells, and to a substantial decrease of the expression of the YAP/TAZ regulated proteins AXL, CTGF, MMP7, and α-SMA (Fig. 5C).

Altogether, these data demonstrated that the downregulation of the expression of TAK1 obtained by using LY2090314 is a valid approach to reduce YAP/TAZ protein levels in vitro and in vivo and, in turn, to modulate the intrinsic chemoresistance of pancreatic cancer.

**Discussion**

In this study, we aimed to identify novel intracellular signaling pathways regulated by TAK1. To our knowledge, this is the first study to demonstrate that TAK1 regulates YAP and TAZ activity by inhibiting their K48-linked ubiquitination and proteasomal degradation in a kinase independent manner. In addition, we demonstrated that the downregulation of the expression of TAK1 through the inhibition of GSK3 is able to largely reduce YAP/TAZ protein levels and, in turn, the transcription of the most relevant YAP/TAZ regulated genes both in vitro and in vivo. In particular, the GSK3 inhibitor LY2090314 proved significantly and consistently effective in decreasing viability, clonogenicity and CSC phenotype in 3 different models of pancreatic cancer cell lines. Most importantly, treatment with LY2090314 sensitized pancreatic cancer cells to the clinically relevant chemotherapeutic agents nab-paclitaxel, gemcitabine, oxaliplatin, and SN38 in vitro, and it potentiated the effects of nab-paclitaxel in inhibiting the growth of an in vivo orthotopic model of pancreatic cancer.

In recent years, several evidences suggested a putative integration of TAK1 and YAP/TAZ, especially in orchestrating canonical and non-canonical WNT signaling. YAP and TAZ have been demonstrated as integral components of the β-catenin destruction complex, which serves as their functional sink. Activation of canonical WNT signaling causes rapid release of YAP/TAZ, leading to the activation of their transcriptional program. Moreover, the presence of YAP/TAZ in the destruction complex is necessary for the recruitment of βTrCP and β-catenin degradation (29). Conversely, in a noncanonical WNT pathway, Wnt5a induces a G-protein–mediated inhibition of LATS kinase activity towards YAP/TAZ. In turn, the stable YAP/TAZ/TEAD

**Table 1. Combination study for nab-paclitaxel and LY2090314.**

<table>
<thead>
<tr>
<th></th>
<th>CI_{50} (±SD)</th>
<th>CI_{50} (±SD)</th>
<th>CI_{50} (±SD)</th>
<th>DRIC_{25} nab-paclitaxel</th>
<th>DRIC_{50} nab-paclitaxel</th>
<th>DRIC_{25} LY2090314</th>
<th>DRIC_{50} LY2090314</th>
<th>DRIC_{25} LY2090314</th>
<th>CI_{25} LY2090314</th>
</tr>
</thead>
<tbody>
<tr>
<td>AsPC1</td>
<td>1.6 ± 0.5</td>
<td>0.59 ± 0.1</td>
<td>0.77 ± 0.1</td>
<td>0.6</td>
<td>2.12</td>
<td>7.1</td>
<td>40.2</td>
<td>7.9</td>
<td>1.6</td>
</tr>
<tr>
<td>PANC1</td>
<td>0.44 ± 0.06</td>
<td>0.35 ± 0.04</td>
<td>0.47 ± 0.08</td>
<td>2.8</td>
<td>5.9</td>
<td>12.7</td>
<td>12.5</td>
<td>5.6</td>
<td>2.5</td>
</tr>
<tr>
<td>MDA-</td>
<td>0.19 ± 0.12</td>
<td>0.25 ± 0.08</td>
<td>0.37 ± 0.24</td>
<td>5.9</td>
<td>4</td>
<td>2.6</td>
<td>60.5</td>
<td>1,223</td>
<td>24,800</td>
</tr>
<tr>
<td>Panc28</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.98</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: CI, combination index; DRI, dose reduction index; ED, effect dose; r, linear correlation coefficient.
transcription complex drives the transcription of secreted factors such as DKK1, which inhibit canonical WNT pathway (30). In this regard, TAK1 has been shown to mediate also noncanonical WNT signaling. TAB1-dependent autophosphorylation and activation of TAK1 were induced by Wnt1 stimulation, thus activating a Nemo-like kinase (NLK)–MAPK cascade, and resulting in a TCF/LEF-dependent destabilization of the β-catenin/TCF complex interaction with DNA (31, 32).

The noncanonical Wnt5a/Ca2⁺ pathway activates TAK1, which triggered metastasis-associated survival signals in circulating tumor cells from pancreatic cancer patients (34). In this article, we

---

**Figure 5.**

Antitumor activity of LY2090314 plus nab-paclitaxel in vivo in AsPC1 pancreatic tumor orthotopic xenografts (n = 10 mice per group). **A,** Tumor volume was quantified as the sum of all detected photons within the region of the tumor per second. Error bars indicate SD. *; P < 0.05, as determined by t test. **B,** Mice were euthanized by cervical dislocation when presented evidence of advanced bulky disease. Survival was estimated since the day of orthotopic pancreatic cancer cells injection until the day of death. Differences among survival duration of mice in each group were determined by log-rank test. *; P < 0.05. **C,** Immunohistochemical analyses. FFPE sections from AsPC1 tumors treated as indicated were stained with the indicated antibodies. 25× magnification images are shown; image inserts show 10× magnification of the same section. Histograms show percentage DAB stained area for 3 independent IHC slides. *; P < 0.05.
and prostate cancer, prospective clinical trials are still required to validate the clinical relevance of these findings. Although the frequent aberrant activity of YAP/TAZ in a variety of human cancers candidates these factors as ideal therapeutic targets, the HIPPO cascade remains largely undruggable. Several other approaches have been attempted to inhibit different signaling pathways involving YAP/TAZ, including small molecule inhibitors [5], RNAi strategies [6], and antisense oligonucleotides [7]. However, the lack of selectivity and toxicity of these agents represented serious limits for their clinical development [8].

More recently, the SREBP/mevalonate pathway has emerged as a potential therapeutic target for pancreatic cancer [9]. The SREBP pathway plays a crucial role in the regulation of lipid metabolism and cholesterol homeostasis, and its activation is involved in the development and progression of various cancers, including pancreatic cancer [10]. The SREBP pathway is activated by the cleavage of SREBP-2, which is regulated by lipases and the expression of SREBP-1c [11]. The activation of SREBP-2 leads to the activation of the mevalonate pathway, which is involved in the synthesis of cholesterol and isoprenoids, and is associated with the activation of the Ras-MAPK signaling pathway [12].

In conclusion, our study demonstrates for the first time a crucial role for TAK1 in controlling the activity of YAP/TAZ in pancreatic cancer. Targeting TAK1 through the inhibition of GSK3 could be a promising approach to modulate the oncogenic functions, and in particular the chemoresistance, sustained by YAP/TAZ in this disease. Our results also highlight the potential use of LY2090314 as a novel agent that warrants further clinical development in integrated therapeutic strategies [13] with chemo- or targeted therapies [14].

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: R. Santoro, M. Zanotto, C. Zecchetto, G. Piro, D. Melisi
Development of methodology: G. Piro, D. Melisi
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): R. Santoro, M. Zanotto, F. Simionato, V. Merz, C. Cavallini, F. Sabbadini, F. Boschi, A. Scarpa, D. Melisi
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): R. Santoro, M. Zanotto, G. Piro, F. Boschi, D. Melisi
Writing, review, and/or revision of the manuscript: R. Santoro, C. Zecchetto, G. Piro, V. Merz, A. Scarpa, D. Melisi
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): D. Melisi
Study supervision: C. Zecchetto, D. Melisi

Acknowledgments
This work was supported by the investigator grants nos. 19111 and 23719 and 5+1000 grant no. 12182 through the Associazione Italiana per la Ricerca sul Cancro (AIRC), by the Ricerca Finalizzata 2016 grant through the Italian Ministry of Health, and by the “Nastro Viola” and “Voglio il Massimo” associations of patients’ donations to D. Melisi. Part of the work was performed at the Laboratorio Universitario di Ricerca Medica (LURM) Research Center, University of Verona. We thank Drs. Michela Deiana, Maria Teresa Valenti, Carmine Carbone, and Lorena Torroni for technical help and Dr. Hayley Louise Salt for data entry and administrative support. We thank Prof Jae-Hyuck Shim for the kind gift of murine wild-type and kinase-dead K63W TAK1 lentiviral expression constructs.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received March 22, 2019; revised July 19, 2019; accepted September 18, 2019; published first September 27, 2019.

References
TAK1 Sustains YAP/TAZ In Pancreatic Cancer


Molecular Cancer Therapeutics

Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer

Raffaela Santoro, Marco Zanotto, Francesca Simionato, et al.

Mol Cancer Ther 2020;19:247-257. Published OnlineFirst September 27, 2019.

Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-19-0270

Supplementary Material
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2019/09/25/1535-7163.MCT-19-0270.DC1

Cited articles
This article cites 40 articles, 11 of which you can access for free at:
http://mct.aacrjournals.org/content/19/1/247.full#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://mct.aacrjournals.org/content/19/1/247.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.